GRAL enters the post-earnings week in an interesting position: the stock beat Q1 estimates, absorbed a 2.3% single-day pullback, and yet short sellers barely flinched — leaving a meaningful short position intact heading into a second event next week.
The Q1 numbers were genuinely better than feared. EPS came in at -$2.29 against a -$2.70 consensus estimate. Revenue of $39.8M edged past the $38.9M forecast. That is a real beat for a pre-profit biotech navigating the path to Medicare reimbursement for its Galleri multi-cancer early detection test. The stock had already rallied 4.2% over the week by the time the print landed on May 5, and that gain held, despite a modest fade into the close.
Short interest tells the story of a patient, unconvicted bear camp rather than an aggressive one. At 17.8% of the free float, the position is material — but it barely moved this week, with shares short edging up just 0.46% over the five sessions. Availability in the lending market is loose, running well above 1,000%, which means new short demand faces no structural barrier. Cost to borrow has also drifted lower — down 25% over the past month to 0.48% — a sign that borrow pressure has eased considerably from the elevated levels seen in late March and early April, when the cost-to-borrow briefly touched 0.71%-0.77%. The short score of 64.4 is elevated in absolute terms but has been range-bound for the past two weeks, suggesting no fresh conviction on either side of the trade. The ORTEX short score is near its highest recent reading, but the flat trajectory underscores the wait-and-see tone.
Options positioning complicates the picture in the bulls' favour. The put/call ratio dropped sharply to 0.46 on May 5 — nearly 1.8 standard deviations below its 20-day average of 0.58. That is a notably call-heavy skew, the most bullish options posture of the year relative to trend. It stands in contrast to the elevated short interest, suggesting that the derivatives market is leaning into the Q1 beat while short sellers have yet to cover. The 52-week PCR range runs from 0.18 to 0.79; Tuesday's reading lands closer to the bullish end of that distribution.
The Street remains cautiously constructive, if not enthused. TD Cowen lifted its target to $69 (from $65) while holding a Buy on Wednesday, and Piper Sandler nudged its target to $56 (from $54) while keeping a Neutral. Those moves are incremental responses to the earnings beat. The consensus aggregates four Hold ratings against a mean price target of $67.71 — implying roughly 24% upside from the $54.40 close. That is meaningful return potential on paper, though the target represents analyst caution recalibrated sharply downward after February's brutal earnings event, which saw the stock fall 57.6% in a single session following a previous print. Guggenheim's current Buy target of $75 looks like an outlier versus the cluster of Neutral-rated targets in the mid-to-high $50s. A data consistency note: several targets set earlier this year ranged from $80 to $130 but were slashed in February and March after that earnings shock — the current analyst landscape reflects the post-reset picture.
The ownership structure adds one notable wrinkle. Former parent ILMN still holds 3.17% of shares, but cut its position by 1.2 million shares as of February. That residual seller is a known quantity for the market, but any further reduction would likely weigh on the float. BlackRock and State Street both added in Q1 2026, a passive-flow signal rather than an active thesis. Meanwhile, the C-suite executed a cluster of open-market sells on April 8 — CEO Bob Ragusa ($6.2M), President Josh Ofman ($3.1M), and CFO Aaron Freidin ($2.3M), all at approximately $49.92. These were sizeable in dollar terms. The April 8 date coincided with a period when the stock was recovering from March lows, so the timing reads as opportunistic rather than alarming — but it is on the record.
The next watch point is a second scheduled event on May 13. GRAIL also announced it will present new data from the NHS-Galleri trial and the PATHFINDER 2 study at the 2026 ASCO Annual Meeting. The convergence of a May earnings event, an ASCO data catalyst, and an unresolved Medicare reimbursement decision means the next ten days carry a concentrated event risk — with call-heavy options positioning and a flat-but-large short base on one side of the ledger, and the February sell-off memory still fresh on the other.
See the live data behind this article on ORTEX.
Open GRAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
